Welcome To BioHealthonomics Inc.

homepage_title

BioHealthonomics Inc. is a clinical stage biotechnology & healthcare company dedicated to developing and commercializing high-impact, effective therapeutics that address critical unmet needs in the treatment of migraine headaches, Parkinson’s disease, Alzheimer’s disease and ALS.  The company plans to develop both a product (histamine dihydrochloride) and an industry unique proprietary technology for the treatment and prevention of these conditions. BioHealthonomics Inc. began operations in July 2011 in Santa Monica, California.

The National Headache Foundation estimates that US businesses lose $50 billion each year because of absenteeism, reduced employee productivity, and medical expenses caused by headaches. (JD Bartleson, Treatment of Migraine Headaches, Mayo Clin. Proc. 1999; 74; 702-708). In the U.S., more than 30 million people suffer from migraines, according to a 2001 report from the Health’s National Institute of Neurological Disorders and Stroke. It is the 12th most disabling disorder in the US. Neurologists agree that safer and more effective prophylactic agents represent the most critical unmet need in the treatment of both episodic and chronic migraine.

Alzheimer’s disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually even the ability to carry out the simplest tasks. In most people with Alzheimer’s, symptoms first appear after age 60. Estimates vary, but experts suggest that as many as 5.1 million Americans may have Alzheimer’s disease.

With the first of the baby boomer generation now turning 65, the U.S. population aged 65 and over is expected to double by 2030. Although Alzheimer’s is not normal aging, age is the biggest risk factor for the disease. Taken together, these factors will result in more and more Americans living with Alzheimer’s – as many as 16 million by 2050, when there will be nearly one million new cases each year.  Caring for people with Alzheimer’s will cost all payers – Medicare, Medicaid, individuals, private insurance and HMOs — $20 trillion over the next 40 years, enough to pay off the national debt and still send a $10,000 check to every man, woman and child in America. In 2012, America will have spent an estimated $200 billion in direct costs for those with Alzheimer’s, including $140 billion in costs to Medicare and Medicaid.

Parkinson’s Disease is one of the most common neurologic disorders, affecting approximately 1% of individuals older than 60 years and causing progressive disability that can be slowed, but not halted, by treatment. Despite extensive research in the area of PD, the precise pathogenesis remains largely unknown. Parkinson’s Disease is characterized by motor and nonmotor (cognitive and limbic) deficits. The economic burden of Parkinson’s disease is at least $14.4 billion a year in the United States, and the prevalence of Parkinson’s will more than double by the year 2040.

BioHealthonomics Inc. intends on advancing its therapies to provide patients with safe and effective treatments in the care of their conditions that address the indications from a fundamental stand point while creating a win-win scenario for patients, doctors, investors, insurance companies and the U.S. healthcare system.